Skip to main content

Table 2 Performance comparison in clinical variables between ARSACS patients at different disease stages

From: From motor performance to participation: a quantitative descriptive study in adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay

 

Total

No walking difficulty

Walking aid

Wheelchair

p-value**

n = 28

n = 7

n = 11

n = 10

Upper limb functions (dexterity, coordination and strength)

 PPT (no. of pegs)

5.2 (2.4)a

7.9 (0.90)

5.4 (1.6)

2.8 (1.7)

< 0.001

  min-max

0.5–9.5

6.5–9.5

3.0–8.5

0.5–6.5

 NHPT (seconds)

58.2 (37.7)

33.8 (3.5)

45.0 (8.8)

89.6 (49.0)

< 0.001

  min-max

28.6–211.2

28.6–37.5

35.1–61.0

35.9–211.2

 SFNT (no. of targets)

11.5 (3.7)

14.4 (4.2)

12.4 (1.7)

8.4 (3.0)

0.002

  min-max

5.5–23.0

10.0–23.0

10.5–15.0

5.5–15.5

 Grip strength (kg)

28.9 (9.8)

30.0 (11.9)

27.8 (10.1)

29.2 (9.0)

0.736

  min-max

11.3–52.3

13.3–44.0

16.7–52.3

11.3–38.3

 Pinch strength (kg)

6.8 (1.9)

7.6 (1.6)

6.1 (1.5)

7.0 (2.3)

0.294

  min-max

3.7–10.5

4.5–9.3

4.1–8.8

3.7–10.5

Lower limb functions (coordination)

 LEMOCOT (no. of targets)

17.0 (10.1)

27.7 (3.6)

19.3 (5.8)

6.9 (7.3)

< 0.001

  min-max

0–34.5

22.0–32.5

13.5–34.5

0–21.5

Mobility and balance

 6MWTb (meters)

235.3 (116.3)

355.0 (78.8)

177.4 (53.9)

35.0c

0.002

  min-max

35.0–459.5

256.0–459.5

99.0–270.0

35.0

 10mWTb (speed, m/s)

0.87 (0.44)

1.33 (0.21)

0.71 (0.26)

0.15 (0.02)c

0.001

  min-max

0.14–1.6

1.1–1.6

0.33–1.2

0.14–0.17

 BBS

22.1 (19.1)

47.3 (5.8)

24.0 (10.6)

2.5 (4.2)

< 0.001

  min-max

0–56

42–56

11–42

0–13

Disease severity

 SPRS

24.3 (11.2)

11.1 (4.3)

21.8 (4.1)

36.1 (6.9)

< 0.001

  min-max

3.0–50.0

3.0–16.0

16.0–28.0

26.0–50.0

 SARA

20.6 (8.9)

10.3 (3.0)

18.0 (2.3)

30.7 (4.5)

< 0.001

  min-max

6.0–36.0

6.0–13.5

13.0–22.0

23.0–36.0

Participation and health-related quality of life

 LIFE-H

7.8 (1.2)

9.3 (0.57)

7.7 (0.50)

6.9 (1.4)

0.001

  min-max

4.0–9.7

8.3–9.7

6.9–8.6

4.0–8.9

 Barthel Index

84.3 (22.1)

99.3 (1.9)

94.1 (7.0)

63.0 (24.9)

< 0.001

  min-max

25–100

95–100

80–100

25–95

 SF-12v2 (MCS)

54.9 (12.8)

51.8 (13.3)

59.9 (9.4)

51.5 (15.0)

0.141

  min-max

13.1–72.5

22.8–61.5

39.8–72.5

13.1–66.2

 SF-12v2 (PCS)

41.4 (5.8)

41.4 (6.6)

39.4 (5.5)

43.6 (5.3)

0.333

  min-max

27.0–51.5

32.3–49.9

27.0–46.7

38.0–51.5

  1. **Comparison between < 40 years and ≥ 40 years using a Krsukal-Wallis Test; results in bold are significant (p-value < 0.05)
  2. aResults are presented as Mean (standard deviation)
  3. b19 participants were able to performed the 6MWT and 20 participants the 10mWT in the total sample
  4. cOne participant out of 10 have performed the 6MWT and two participants performed the 10mWT in the Wheelchair disease stage